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The development of a RT-QI project has been demanded 
by the Belgian national government as a potential tool to 
help RT departments to further optimise the quality of 
patient care. Although participation of each individual 
department is on voluntary basis, it has been shown 
feasible to collect defined QIs at national level with an 
almost complete participation rate. The analysis and 
generation of benchmarking documents guide centres in 
their quality improvement initiatives at departmental 
level and support national quality improvement 
initiatives. 
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Purpose or Objective 
Palliative radiotherapy (PRT) benefits many patients 
with breast cancer, but optimal utilization rates remain 
undefined. The objective of this study was to estimate the 
appropriate PRT rate for the general breast cancer 
population.  
Material and Methods 
Ontario’s population-based cancer registry identified 
patients who died of breast cancer between 2009 and 
2013. Multivariate analysis identified health systems 
factors affecting the use of PRT for breast cancer, 
enabling us to define a benchmark population with 
unimpeded access to PRT. Proportion of cases treated in 
the last 5 years of life (PRT5y) was standardized to overall 
population characteristics. Benchmarks were compared to 
province-wide PRT5y rates. 
Results 
Overall, 36.2% of 11,075 patients who died of breast 
cancer between 2009 and 2013 received PRT at least once 
in the last 5 years of life. Availability of RT at the 
diagnosing hospital was the dominant determinant of 
increased PRT use; socioeconomic status and residential 
distance to nearest RT centre did not have a significant 
effect. Patients diagnosed at hospitals with on-site RT 
were therefore designated the benchmark 
population. The standardized benchmark for 
PRT5y was 40.7%, compared to the province-wide rate 
of 36.2%. Indication-specific benchmarks demonstrated 
that shortfalls in PRT use were highest for locoregional RT, 
followed by brain and bone metastases (Table). Age-
specific benchmarks demonstrated that shortfalls in PRT 
use were >3 times greater in patients >70 vs ≤70 
years. The extent of the shortfall varied widely amongst 
Ontario regions (Figure). 
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Age ≤70 >70 
55.7% (50.5%, 60.8%) 
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Total  40.7% (37.8%, 43.6%) 36.2% (35.3%, 37.0%) 11.1% 
 
†PRT5y rate among patients whose cancer was diagnosed 
at a hospital with RT on site, standardized to the 
distribution of life expectancy in the overall population;  
*Shortfall = Unmet Need / Total Need = (Benchmark rate 
- Actual rate) / Benchmark rate x 100% 
 
Figure: Inter-county variations in shortfalls in the use of 





In a standardized benchmark Ontario population with 
unimpeded access to RT, 40.7% of patients who died of 
breast cancer received PRT, compared to 36.2% of the 
overall population. The gap between actual and optimal 
PRT rates was greatest in the elderly and varied widely 
across regions. An effort should be made to reduce the 
large age-related and regional differences in PRT use for 
patients with advanced breast cancer. This method 
provides a rational estimate of appropriate treatment 
rates required for monitoring and improving access to 
cancer care. 
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Purpose or Objective 
Non-adherence to external radiotherapy is an aspect of 
treatment which has not been fully explored. The 
objective of this study is to analyse the relevance of this 
problem and its impact on 1-year survival 
Material and Methods 
A Cohort study design was carried out with a prospective 
follow-up of cancer patients with indication of external 
radiotherapy. All patients with indication of treatment 
during year 2016 in the hospital of the public sector in 
Catalonia were included. Adherence was deemed 
acceptable if total dose received was over 90% of the dose 
prescribed. Statistical analysis was performed according 
to type of tumour, intention of treatment and age. 
Logistic regression was carried out to assess factors 
associated to adherence and Cox analysis was applied to 
assess their relationship with survival 
Results 
In total, 15.157 patients were included with an average 
age of 64.6 (± 14.0); 51.3% were males. Most frequent 
tumours were breast (27.4%), lung (16,1%) and prostate 
(12.4%). Radical intent was indicated in 69.2% of cases and 
18.7% of patients received concomitant chemo. At least 
one day interruption of treatment, excluding public 
holidays, was observed in 41.8% of cases. The reasons 
(multiple choice) for these interruptions were, 75.8% due 
to problems with the equipment, 17.9% for medical 
reason, 7.9% due to the patient preference and 20.9% for 
others reasons. Patient adherence was of 95.5% of patients 
(receiving more than 90% of total dose). Radical intent was 
related (OR: 3.11; IC: 95%: 2.6-3.7) to better adherence. 
Older age was associated with lower probability of 
adherence. Head and neck, lung, digestive other than 
rectal and bone (including metastasis) cancers were 
associated with lower probability of adherence; while 
breast and prostate  cancer patients were associated with 
significantly higher than average adherence.  One-year 
survival was signifycantly higher among adherent patients, 
both in radical (HR: 4.5; IC95%:3.8-5.4) and palliative (HR: 
2.1; IC95%:1.8-2.4) intent 
Conclusion 
Adherence of treatment is very high among this cohort of 
population based patients receiving treatment in the 
public sector in Catalonia. Lack of adherence is related to 
lower probability of survival and this factor should be 
considered in the follow-up of patients with radiotherapy 
treatment
